New schizophrenia drug KarXT checked for risky drug interactions
NCT ID NCT07118215
First seen Jun 26, 2026 · Last updated Jul 23, 2026 · Updated 3 times
Summary
This early-stage study is testing whether KarXT, a new drug for schizophrenia, changes how the body processes three other common medications (midazolam, fexofenadine, and digoxin). Sixty healthy adults will take KarXT along with each of these drugs to see if their levels in the blood are affected. The goal is to identify any potential drug interactions before KarXT is used more widely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KarXT (a combination of xanomeline and trospium chloride)
- What this could lead to
- If successful, this study will show whether KarXT can be safely taken with other common medications without changing their effects.
- What could go wrong
- This is an early phase 1 study in only 60 healthy volunteers, not patients. It only measures drug levels, not real-world safety or effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Local Institution - 0001
Lenexa, Kansas, 66219-9746, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults